company background image
CBL

Control BionicsASX:CBL Stock Report

Market Cap

AU$50.1m

7D

-6.7%

1Y

n/a

Updated

18 Oct, 2021

Data

Company Financials +
CBL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CBL Overview

Control Bionics Limited engages in the research, development, commercialization, and sale of assistive communications technology systems that allows user with speech and movement disabilities in Australia and North America.

Control Bionics Competitors

Tobii

OM:TOBII

kr6.4b

Price History & Performance

Summary of all time highs, changes and price drops for Control Bionics
Historical stock prices
Current Share PriceAU$0.56
52 Week HighAU$0.52
52 Week LowAU$1.24
Beta0
1 Month Change-8.20%
3 Month Change-11.11%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-52.54%

Recent News & Updates

Sep 17
We're Hopeful That Control Bionics (ASX:CBL) Will Use Its Cash Wisely

We're Hopeful That Control Bionics (ASX:CBL) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

CBLAU Medical EquipmentAU Market
7D-6.7%-0.7%0.9%
1Yn/a-4.9%20.2%

Return vs Industry: Insufficient data to determine how CBL performed against the Australian Medical Equipment industry.

Return vs Market: Insufficient data to determine how CBL performed against the Australian Market.

Price Volatility

Is CBL's price volatile compared to industry and market?
CBL volatility
CBL Beta0
Industry Beta0.57
Market Beta1

Stable Share Price: CBL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CBL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aRob Wonghttps://www.controlbionics.com

Control Bionics Limited engages in the research, development, commercialization, and sale of assistive communications technology systems that allows user with speech and movement disabilities in Australia and North America. It offers NeuroNode Trilogy, a wearable device solution for those living with paralysis and loss of speech; NeuroNode3, a wearable EMG control device; and Control Bionics CCS that allow users to communicate with friends and family, send and receive emails and text messages, browse the web, watch videos and movies, read the news, play games, control their home environmental control systems, and others. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020.

Control Bionics Fundamentals Summary

How do Control Bionics's earnings and revenue compare to its market cap?
CBL fundamental statistics
Market CapAU$50.13m
Earnings (TTM)-AU$3.55m
Revenue (TTM)AU$4.09m

11.4x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBL income statement (TTM)
RevenueAU$4.09m
Cost of RevenueAU$1.43m
Gross ProfitAU$2.66m
ExpensesAU$6.21m
Earnings-AU$3.55m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.043
Gross Margin65.02%
Net Profit Margin-86.85%
Debt/Equity Ratio0%

How did CBL perform over the long term?

See historical performance and comparison

Valuation

Is Control Bionics undervalued compared to its fair value and its price relative to the market?

2.73x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CBL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CBL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CBL is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: CBL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CBL is good value based on its PB Ratio (2.7x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Control Bionics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

24.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CBL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CBL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CBL's revenue (34.7% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: CBL's revenue (34.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CBL is forecast to be unprofitable in 3 years.


Past Performance

How has Control Bionics performed over the past 5 years?

-253.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CBL is currently unprofitable.

Growing Profit Margin: CBL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CBL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CBL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: CBL has a negative Return on Equity (-20.69%), as it is currently unprofitable.


Financial Health

How is Control Bionics's financial position?


Financial Position Analysis

Short Term Liabilities: CBL's short term assets (A$13.7M) exceed its short term liabilities (A$1.2M).

Long Term Liabilities: CBL's short term assets (A$13.7M) exceed its long term liabilities (A$16.9K).


Debt to Equity History and Analysis

Debt Level: CBL is debt free.

Reducing Debt: CBL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CBL has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 40.9% each year.


Dividend

What is Control Bionics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Rob Wong

no data

Tenure

Mr. Robert William Wong, also known as Rob, serves as the Chief Executive Officer and Board Member at Control Bionics Limited. He joined Control Bionics in early 2017 and he has led the way in developing t...


Leadership Team

Experienced Management: CBL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CBL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: CBL only recently listed within the past 12 months.


Top Shareholders

Company Information

Control Bionics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Control Bionics Limited
  • Ticker: CBL
  • Exchange: ASX
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$50.127m
  • Shares outstanding: 83.55m
  • Website: https://www.controlbionics.com

Location

  • Control Bionics Limited
  • 171 Union Road
  • Suite G.03
  • Surrey Hills
  • Victoria
  • 3127
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:02
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.